Sugi Predict

Sugi Predict / Compounds / SCHEMBL17645765

SCHEMBL17645765

SCHEMBL17645765

COC(=O)c1ccc(C2CC2)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.57
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ KDM4E B2RXH2 2/20 0.54
▸ KMT2A Q03164 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ SPR P35270 1/20 0.43
▸ CA1 P00915 2/20 0.43
▸ CA2 P00918 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ CA14 Q9ULX7 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ HPGDS O60760 1/20 0.42
▸ ALOX5AP P20292 1/20 0.42
▸ FEN1 P39748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25953854 1.00 MAPK1 (0.57) MAPK1L3MBTL1KDM4EKMT2ARAB9A
SCHEMBL20400835 0.92 MAPK1 (0.53) MAPK1L3MBTL1KDM4EKMT2ARAB9A
SCHEMBL15984766 0.88 MAPK1 (0.49) MAPK1L3MBTL1KDM4EKMT2ARAB9A
SCHEMBL21063407 0.86 MAPK1 (0.53) MAPK1L3MBTL1KDM4EKMT2ARAB9A
SCHEMBL4482079 0.84 MAPK1 (0.44) MAPK1L3MBTL1KDM4EKMT2ARAB9A
SCHEMBL25331810 0.83 CA12 (0.47) L3MBTL1KMT2ARAB9ANPC1CA1
SCHEMBL13490414 0.82 MAPK1 (0.46) MAPK1
SCHEMBL17129236 0.81 RAB9A (0.55) KMT2ARAB9ANPC1ALDH1A1MEN1
SCHEMBL18397093 0.81 MEN1 (0.43) L3MBTL1KMT2AMEN1HPGDSHRH3
SCHEMBL29539403 0.81 MEN1 (0.43) L3MBTL1KMT2AMEN1HPGDSHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 — — US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 — — US disclosed
EP-3976608-B1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2023-11-08 — — EP disclosed
EP-3976608-B1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2023-11-08 — — EP disclosed
US-11634391-B2 Compounds which are inhibitors of Notum UCL BUSINESS LTD (GB) 2023-04-25 — — US disclosed
US-20230078112-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. 2023-03-16 — — US disclosed
CN-113264945-B Spiro derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2022-11-22 — — CN disclosed
US-20220332699-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SAGE THERAPEUTICS, INC. 2022-10-20 — — US disclosed
EP-3976186-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Sage Therapeutics, Inc. (US) 2022-04-06 — — EP disclosed
EP-3976608-A1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2022-04-06 — — EP disclosed
US-20190233417-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-08-01 — — US disclosed
US-20190233417-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-08-01 — — US disclosed
US-10253023-B2 Heteroaryl compounds as BTK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2019-04-09 — — US disclosed
EP-3204382-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2017-08-16 — — EP disclosed
CN-107001362-A Heteroaryl compound as BTK inhibitor and application thereof 默克专利有限公司 2017-08-01 — — CN disclosed
WO-2016057500-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-04-14 — — WO disclosed
WO-2016057500-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-04-14 — — WO disclosed
US-20160096834-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-04-07 — — US disclosed
US-20160096834-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-04-07 — — US disclosed
US-20160096834-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10253023-B2 Heteroaryl compounds as BTK inhibitors and uses thereof BTK, SYK, LYN MAPK1 1046/4885L3MBTL1 1862/4885KDM4E 935/4885
US-20260049074-A1 THIADIAZOLYL DERIVATIVES POLH, POLM, POLD1 MAPK1 4035/4885L3MBTL1 1234/4885KDM4E 3719/4885
US-20190233417-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF BTK, SYK, LYN MAPK1 1065/4885L3MBTL1 1551/4885KDM4E 1104/4885
US-20160096834-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF BTK, SYK, LYN MAPK1 1046/4885L3MBTL1 1862/4885KDM4E 935/4885
US-11634391-B2 Compounds which are inhibitors of Notum NOTUM, GOT2, GOT1 MAPK1 1270/4885L3MBTL1 2093/4885KDM4E 3907/4885
US-20220332699-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE CYP46A1, CYP26A1, CYP21A2 MAPK1 927/4885L3MBTL1 4695/4885KDM4E 2676/4885
US-20230078112-A1 THIADIAZOLYL DERIVATIVES POLQ, POLK, POLA1 MAPK1 2785/4885L3MBTL1 2727/4885KDM4E 3851/4885
US-12509454-B2 Thiadiazolyl derivatives POLD1, POLQ, DNA2 MAPK1 2841/4885L3MBTL1 3784/4885KDM4E 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.